| Year |
Citation |
Score |
| 2023 |
Jones TM, Espitia CM, Chipollini J, Lee BR, Wertheim JA, Carew JS, Nawrocki ST. Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity. Cancer Research Communications. 3: 245-257. PMID 36860653 DOI: 10.1158/2767-9764.CRC-22-0340 |
0.371 |
|
| 2022 |
Jones TM, Espitia CM, Ooi A, Bauman JE, Carew JS, Nawrocki ST. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. Cell Death & Disease. 13: 350. PMID 35428778 DOI: 10.1038/s41419-022-04798-6 |
0.385 |
|
| 2021 |
Islam S, Espitia CM, Persky DO, Carew JS, Nawrocki ST. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma. Viruses. 13. PMID 34372612 DOI: 10.3390/v13071406 |
0.342 |
|
| 2021 |
Islam S, Espitia CM, Persky DO, Carew JS, Nawrocki ST. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma Viruses. 13: 1406. DOI: 10.3390/v13071406 |
0.342 |
|
| 2020 |
Islam S, Espitia CM, Persky DO, Carew JS, Nawrocki ST. Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. Blood Advances. 4: 5297-5310. PMID 33108458 DOI: 10.1182/bloodadvances.2020002297 |
0.334 |
|
| 2020 |
Nawrocki ST, Wang W, Carew JS. Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance. Cancers. 12. PMID 33081217 DOI: 10.3390/cancers12103005 |
0.356 |
|
| 2020 |
Usman RM, Razzaq F, Akbar A, Farooqui AA, Iftikhar A, Latif A, Hassan H, Zhao J, Carew JS, Nawrocki ST, Anwer F. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia-Pacific Journal of Clinical Oncology. PMID 32970929 DOI: 10.1111/ajco.13449 |
0.336 |
|
| 2020 |
Jones TM, Carew JS, Nawrocki ST. Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. Cancers. 12. PMID 32392870 DOI: 10.3390/Cancers12051185 |
0.455 |
|
| 2020 |
Kathawala RJ, Espitia CM, Jones TM, Islam S, Gupta P, Zhang YK, Chen ZS, Carew JS, Nawrocki ST. ABCG2 Overexpression Contributes to Pevonedistat Resistance. Cancers. 12. PMID 32059437 DOI: 10.3390/Cancers12020429 |
0.422 |
|
| 2020 |
Jones T, Espitia C, Carew J, Nawrocki ST. Abstract 5211: Targeting Neddylation synergistically augments the activity of cisplatin in head and neck cancer models to yield long-term survival by modulating key DNA damage and redox pathways Cancer Research. 80: 5211-5211. DOI: 10.1158/1538-7445.Am2020-5211 |
0.48 |
|
| 2019 |
Jones TM, Espitia C, Wang W, Nawrocki ST, Carew JS. Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies. Cancer Communications (London, England). 39: 72. PMID 31706349 DOI: 10.1186/S40880-019-0418-0 |
0.391 |
|
| 2019 |
Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, Maciejewski JP, Carew JS. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. Leukemia. PMID 31358855 DOI: 10.1038/S41375-019-0529-2 |
0.403 |
|
| 2019 |
Mahalingam D, Carew JS, Espitia CM, Cool RH, Giles FJ, de Jong S, Nawrocki ST. Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models. Cancers. 11. PMID 31248045 DOI: 10.3390/Cancers11070895 |
0.563 |
|
| 2019 |
Anwer F, Gee KM, Iftikhar A, Baig M, Russ AD, Saeed S, Zar MA, Razzaq F, Carew J, Nawrocki S, Al-Kateb H, Cavalcante Parr NN, McBride A, Valent J, Samaras C. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. PMID 31036508 DOI: 10.1016/J.Clml.2019.03.017 |
0.384 |
|
| 2019 |
Carew JS, Espitia CM, Zhao W, Visconte V, Anwer F, Kelly KR, Nawrocki ST. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. Blood Advances. 3: 1318-1329. PMID 31015208 DOI: 10.1182/Bloodadvances.2018026484 |
0.483 |
|
| 2019 |
Cimino PJ, Huang L, Du L, Wu Y, Bishop J, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Carew J, Nawrocki S, Jordan MA, Wilson L, Lloyd GK, Wirsching HG. Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. Biomedical Reports. 10: 218-224. PMID 30972217 DOI: 10.3892/Br.2019.1196 |
0.449 |
|
| 2019 |
Adema V, Kerr CM, Kongkiatkamon S, Durrani J, Awada H, Hutter S, Fung K, Gould F, Snider CA, Advani AS, Carraway HE, Kelly KR, Nawrocki ST, Saunthararajah Y, Carew JS, et al. CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q) Blood. 134: 1281-1281. DOI: 10.1182/Blood-2019-129196 |
0.383 |
|
| 2019 |
Visconte V, Adema V, Tiwari AD, Kerr CM, Awada H, Przychodzen B, Noe A, Toth R, Snider C, Parker Y, Fedorov Y, Adams D, Carraway HE, Advani AS, Kelly KR, ... Nawrocki ST, et al. Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia Blood. 134: 564-564. DOI: 10.1182/Blood-2019-129189 |
0.398 |
|
| 2018 |
Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST. Oncolytic Viruses for Multiple Myeloma Therapy. Cancers. 10. PMID 29903988 DOI: 10.3390/Cancers10060198 |
0.391 |
|
| 2018 |
Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers. 10. PMID 29799479 DOI: 10.3390/Cancers10060160 |
0.388 |
|
| 2018 |
Islam S, Espitia CM, Qu N, Persky D, Carew JS, Nawrocki ST. Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma Blood. 132: 2941-2941. DOI: 10.1182/Blood-2018-99-119152 |
0.375 |
|
| 2018 |
Visconte V, Przychodzen BP, Adema V, Hirsch CM, Noe A, Toth R, Snider C, Awada H, Graham AC, Parker Y, Fedorov Y, Adams D, Carraway HE, Advani AS, Radivoyevitch T, ... ... Nawrocki ST, et al. Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies Blood. 132: 211-211. DOI: 10.1182/Blood-2018-99-116411 |
0.407 |
|
| 2017 |
Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas. Oncotarget. 8: 86769-86783. PMID 29156834 DOI: 10.18632/Oncotarget.21423 |
0.48 |
|
| 2017 |
Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. PMID 28832023 DOI: 10.1038/Leu.2017.272 |
0.328 |
|
| 2017 |
Carew JS, Nawrocki ST. Drain the lysosome: development of the novel orally available autophagy inhibitor ROC-325. Autophagy. 0. PMID 28118053 DOI: 10.1080/15548627.2017.1280222 |
0.467 |
|
| 2017 |
Nawrocki ST, Kelly KR, Espitia CM, Carew JS. Abstract NTOC-102: TARGETING NEDDYLATION TO OVERCOME CISPLATIN RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-102 |
0.493 |
|
| 2016 |
Carew JS, Espitia CM, Zhao W, Han Y, Visconte V, Phillips JG, Nawrocki S. Disruption of autophagic degradation with ROC-325 antagonizes renal cell carcinoma pathogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27881580 DOI: 10.1158/1078-0432.Ccr-16-1742 |
0.431 |
|
| 2016 |
Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, Sekeres MA, Maciejewski JP, Carew JS. Complete mutational spectrum of the autophagy interactome: A novel class of tumor suppressor genes in myeloid neoplasms. Leukemia. PMID 27773925 DOI: 10.1038/Leu.2016.295 |
0.331 |
|
| 2016 |
Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel T, Mahalingam D. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget. PMID 27463016 DOI: 10.18632/Oncotarget.10824 |
0.487 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Nawrocki ST, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.341 |
|
| 2016 |
Patel SR, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel TJ, Mahalingam D. Effect of vorinostat (VOR) and hydroxychloroquine (HCQ) on immunity and autophagy in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 34: 670-670. DOI: 10.1200/Jco.2016.34.4_Suppl.670 |
0.411 |
|
| 2016 |
Nawrocki ST, Han Y, Visconte V, Phillips JG, Przychodzen BP, Maciejewski JP, Kelly KR, Carew JS. Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity Blood. 128: 525-525. DOI: 10.1182/Blood.V128.22.525.525 |
0.563 |
|
| 2016 |
Kelly KR, Wu K, Tsao-Wei D, Groshen S, Triche TJ, Mohrbacher A, Chang G, Fernando D, Siddiqi IN, Coffey M, Gill G, Lee A, Carew JS, Nawrocki ST. Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood. 128: 4507-4507. DOI: 10.1182/Blood.V128.22.4507.4507 |
0.358 |
|
| 2016 |
Visconte V, Przychodzen BP, Nawrocki ST, Thota S, Kelly KR, Patel B, Hirsch CM, Carraway HE, Parker Y, Lindner D, Sekeres MA, Rogers HJ, Maciejewski JP, Carew JS. Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes Blood. 128: 4301-4301. DOI: 10.1182/Blood.V128.22.4301.4301 |
0.318 |
|
| 2016 |
Visconte V, Nawrocki ST, Przychodzen BP, Kelly KR, Yin M, Parker Y, Clemente MJ, Barnard J, Advani AS, Carraway HE, Sekeres MA, Lindner D, Rogers HJ, Maciejewski JP, Carew JS. Targeting Autophagy in Myelodysplastic Syndromes Blood. 128: 4295-4295. DOI: 10.1182/Blood.V128.22.4295.4295 |
0.399 |
|
| 2016 |
Kelly KR, Espitia CM, Zhao W, Visconte V, Coffey M, Carew JS, Nawrocki ST. A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma Blood. 128: 3960-3960. DOI: 10.1182/Blood.V128.22.3960.3960 |
0.404 |
|
| 2015 |
Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. PMID 26513296 DOI: 10.18632/Oncotarget.5753 |
0.471 |
|
| 2015 |
Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia. PMID 26369982 DOI: 10.1038/Leu.2015.250 |
0.385 |
|
| 2015 |
Mahalingam D, Patel S, Nuovo G, Gill G, Selvaggi G, Coffey M, Nawrocki ST. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. Bmc Cancer. 15: 513. PMID 26156229 DOI: 10.1186/S12885-015-1518-0 |
0.437 |
|
| 2015 |
Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus. Molecular Cancer Therapeutics. 14: 1404-13. PMID 25808836 DOI: 10.1158/1535-7163.Mct-14-1036 |
0.539 |
|
| 2015 |
Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA, Maciejewski JP, Carew JS. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 439-47. PMID 25388161 DOI: 10.1158/1078-0432.Ccr-14-1960 |
0.354 |
|
| 2015 |
Carew JS, Espitia CM, Zhao W, Visconte V, Kelly KR, Nawrocki ST. Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition Blood. 126: 3022-3022. DOI: 10.1182/Blood.V126.23.3022.3022 |
0.546 |
|
| 2015 |
Nawrocki ST, Espitia CM, Visconte V, Han Y, Kelly KR, Carew JS. Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma Blood. 126: 1807-1807. DOI: 10.1182/Blood.V126.23.1807.1807 |
0.488 |
|
| 2015 |
Visconte V, Kelly KR, Nawrocki ST, Han Y, Carraway HE, Advani AS, Maciejewski JP, Rogers HJ, Sekeres MA, Carew JS. Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications Blood. 126: 1647-1647. DOI: 10.1182/Blood.V126.23.1647.1647 |
0.349 |
|
| 2015 |
Nawrocki ST, Han Y, Moigne RL, Visconte V, Przychodzen B, Rolfe M, Djakovic S, Anderson D, Wustrow D, Zhou H, Wong S, Advani A, Carraway HE, Maciejewski JP, Sekeres MA, et al. Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML Blood. 126: 1350-1350. DOI: 10.1182/Blood.V126.23.1350.1350 |
0.545 |
|
| 2015 |
Visconte V, Nawrocki ST, Kelly KR, Han Y, Possemato A, Beausoleil S, Nazha A, Maciejewski JP, Carraway HE, Advani AS, Sekeres MA, Carew JS. Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy Blood. 126: 1271-1271. DOI: 10.1182/Blood.V126.23.1271.1271 |
0.46 |
|
| 2015 |
Lloyd GK, Du L, Lee G, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Nawrocki S, Carew J, Huang L. Abstract A184: Activity of plinabulin in tumor models with Kras mutations Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A184 |
0.389 |
|
| 2015 |
Mahalingam D, Goel S, Coffey M, Noronha N, Selvaggi G, Nawrocki S, Nuovo G, Mita M. P-175Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv233.175 |
0.359 |
|
| 2014 |
Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 10: 1403-14. PMID 24991835 DOI: 10.4161/Auto.29231 |
0.399 |
|
| 2014 |
Carew JS, Espitia CM, Zhao W, Kelly KR, Nawrocki ST. Targeting HDAC6 Is a Novel Approach to Augment the Therapeutic Benefit of Bromodomain Inhibition in Multiple Myeloma Blood. 124: 4760-4760. DOI: 10.1182/Blood.V124.21.4760.4760 |
0.536 |
|
| 2014 |
Tohme R, Moigne RL, Przychodzen BP, Han Y, Rolfe M, Carraway HE, Djakovic S, Anderson D, Wustrow D, Zhou H, Wong S, Kelly KR, Saunthararajah Y, Advani AS, Maciejewski JP, ... ... Nawrocki ST, et al. Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy Blood. 124: 3766-3766. DOI: 10.1182/Blood.V124.21.3766.3766 |
0.548 |
|
| 2013 |
Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer. 12: 104. PMID 24025152 DOI: 10.1186/1476-4598-12-104 |
0.485 |
|
| 2013 |
Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death & Disease. 4: e728. PMID 23868061 DOI: 10.1038/Cddis.2013.259 |
0.527 |
|
| 2013 |
Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3577-90. PMID 23633453 DOI: 10.1158/1078-0432.Ccr-12-3212 |
0.397 |
|
| 2013 |
Mita MM, Mahalingam D, Sarantopoulos J, Amaravadi R, Mita A, Curiel T, Nawrocki S, Giles F, Carew J. Abstract 1686: A Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), pharmacokinetic (PK) and pharmacodynamic (PD) parameters of hydroxychloroquine (HCQ) in combination with vorinostat (V) in patients with advanced solid tumors - final results. Cancer Research. 73: 1686-1686. DOI: 10.1158/1538-7445.Am2013-1686 |
0.393 |
|
| 2012 |
Carew JS, Kelly KR, Nawrocki ST. Autophagy as a target for cancer therapy: new developments. Cancer Management and Research. 4: 357-65. PMID 23091399 DOI: 10.2147/Cmar.S26133 |
0.512 |
|
| 2012 |
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, ... ... Nawrocki ST, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8: 445-544. PMID 22966490 DOI: 10.4161/Auto.19496 |
0.498 |
|
| 2012 |
Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opinion On Investigational Drugs. 21: 1563-73. PMID 22799561 DOI: 10.1517/13543784.2012.707192 |
0.413 |
|
| 2012 |
Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. International Journal of Cancer. Journal International Du Cancer. 131: 2693-703. PMID 22488249 DOI: 10.1002/Ijc.27579 |
0.443 |
|
| 2012 |
Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, et al. Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Molecular Cancer Therapeutics. 11: 1432-42. PMID 22474168 DOI: 10.1182/Blood.V112.11.384.384 |
0.396 |
|
| 2012 |
Carew JS, Esquivel JA, Espitia CM, Schultes CM, Mülbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. Plos One. 7: e31120. PMID 22295124 DOI: 10.1371/Journal.Pone.0031120 |
0.43 |
|
| 2012 |
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki ST. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 31: 3023-38. PMID 22002308 DOI: 10.1038/Onc.2011.478 |
0.497 |
|
| 2012 |
Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investigational New Drugs. 30: 1065-73. PMID 21327495 DOI: 10.1007/S10637-011-9642-4 |
0.35 |
|
| 2012 |
Mahalingam D, Mita MM, Sarantopoulos J, Wood L, Mita AC, Curiel TJ, Argiris A, Nawrocki ST, Carew JS, Giles FJ. Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors. Journal of Clinical Oncology. 30: 3073-3073. DOI: 10.1200/Jco.2012.30.15_Suppl.3073 |
0.425 |
|
| 2012 |
Carew JS, Espitia CM, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Abstract 2717: Reolysin: A novel reovirus-based agent that induces endoplasmic reticular stress in RAS-activated pancreatic cancer Cancer Research. 72: 2717-2717. DOI: 10.1158/1538-7445.Am2012-2717 |
0.36 |
|
| 2011 |
Mahalingam D, Espitia CM, Medina EC, Esquivel JA, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. British Journal of Cancer. 105: 1563-73. PMID 22015557 DOI: 10.1038/Bjc.2011.426 |
0.429 |
|
| 2011 |
Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Targeting aurora kinases in cancer treatment. Current Drug Targets. 12: 2067-78. PMID 21777198 DOI: 10.2174/138945011798829410 |
0.419 |
|
| 2011 |
Swords R, Kelly K, Carew J, Nawrocki ST, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim kinases: new targets for drug development. Current Drug Targets. 12: 2059-2066. PMID 21777193 DOI: 10.2174/138945011798829447 |
0.364 |
|
| 2011 |
Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, de Jong S, Nawrocki ST. Targeting TRAIL towards the clinic. Current Drug Targets. 12: 2079-90. PMID 21777191 DOI: 10.2174/138945011798829357 |
0.498 |
|
| 2011 |
Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncology. 6: 17-27. PMID 21547705 DOI: 10.1007/S11523-011-0167-8 |
0.49 |
|
| 2011 |
Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Targeted Oncology. 6: 53-61. PMID 21499765 DOI: 10.1007/S11523-011-0175-8 |
0.401 |
|
| 2011 |
Carew JS, Espitia CM, Esquivel JA, Mahalingam D, Kelly KR, Reddy G, Giles FJ, Nawrocki ST. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. The Journal of Biological Chemistry. 286: 6602-13. PMID 21148553 DOI: 10.1074/Jbc.M110.151324 |
0.53 |
|
| 2011 |
Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. Journal of Cellular and Molecular Medicine. 15: 2057-70. PMID 21091633 DOI: 10.1111/J.1582-4934.2010.01218.X |
0.486 |
|
| 2011 |
Nawrocki ST, Espitia CM, Kelly KR, Bornmann WG, Carew JS. Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Acute Myeloid Leukemia Blood. 118: 84-84. DOI: 10.1182/Blood.V118.21.84.84 |
0.552 |
|
| 2011 |
Griffin P, Nawrocki ST, Satou T, Espitia CM, Kelly KR, Hasegawa M, Padmanabhan S, Romanelli A, Jong Rd, Carew JS. The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies Blood. 118: 581-581. DOI: 10.1182/Blood.V118.21.581.581 |
0.534 |
|
| 2010 |
Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 115: 3796-800. PMID 20203261 DOI: 10.1182/Blood-2009-11-254862 |
0.495 |
|
| 2010 |
Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 141-53. PMID 20028765 DOI: 10.1158/1078-0432.Ccr-09-1385 |
0.551 |
|
| 2010 |
Carew JS, Medina EC, Esquivel JA, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. Journal of Cellular and Molecular Medicine. 14: 2448-59. PMID 19583815 DOI: 10.1111/J.1582-4934.2009.00832.X |
0.522 |
|
| 2010 |
Nawrocki ST, Kelly KR, Oberheu K, Mahalingam D, Smith PG, Carew JS. Disrupting NEDD8-Mediated Protein Turnover with MLN4924 Significantly Augments the Efficacy of Cytarabine Blood. 116: 3255-3255. DOI: 10.1182/Blood.V116.21.3255.3255 |
0.54 |
|
| 2010 |
Kelly KR, Oberheu K, Medina E, Espitia CM, Mahalingam D, Taverna P, Choy GS, Nawrocki ST, Giles FJ, Carew JS. Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia Blood. 116: 3253-3253. DOI: 10.1182/Blood.V116.21.3253.3253 |
0.527 |
|
| 2010 |
Mahalingam D, Bansal S, Medina E, Kelly K, Swords R, Cool R, Jong Sd, Carew JS, Giles FJ, Nawrocki ST. Abstract 669: Sunitinib enhances TRAIL-induced apoptosis in preclinical colon cancer models Cancer Research. 70: 669-669. DOI: 10.1158/1538-7445.Am10-669 |
0.569 |
|
| 2009 |
Mahalingam D, Medina E, Swords RT, Kelly KR, Carew JS, Robbert CH, Szegezdi E, Francis GJ, de Jong S, Nawrocki ST. Effect of sunitinib on TRAIL-induced apoptosis in preclinical colon cancer models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14633. PMID 27964192 DOI: 10.1200/Jco.2009.27.15_Suppl.E14633 |
0.481 |
|
| 2009 |
Kelly K, Nawrocki ST, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer Expert Opinion On Biological Therapy. 9: 817-830. PMID 19527106 DOI: 10.1517/14712590903002039 |
0.414 |
|
| 2009 |
Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opinion On Emerging Drugs. 14: 311-28. PMID 19466902 DOI: 10.1517/14728210902972502 |
0.402 |
|
| 2009 |
Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Current Problems in Cancer. 33: 73-111. PMID 19409299 DOI: 10.1016/J.Currproblcancer.2009.03.001 |
0.324 |
|
| 2009 |
Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy British Journal of Cancer. 100: 1523-1529. PMID 19401686 DOI: 10.1038/Sj.Bjc.6605066 |
0.329 |
|
| 2009 |
Kelly KR, Swords RT, Mahalingam D, Nawrocki ST, Medina E, Smith S, Padmanabhan S, Ecsedy J, Cahill MR, Giles FJ, Carew JS. The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine. Blood. 114: 2087-2087. DOI: 10.1182/Blood.V114.22.2087.2087 |
0.558 |
|
| 2009 |
Swords RT, Kelly KR, Smith PG, Gansey JJ, Mahalingam D, Padmanabhan S, O'Dwyer MC, Nawrocki ST, Giles FJ, Carew JS. MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia. Blood. 114: 1021-1021. DOI: 10.1182/Blood.V114.22.1021.1021 |
0.528 |
|
| 2009 |
Mahalingam D, Medina E, Swords RT, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST. Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B272 |
0.498 |
|
| 2008 |
Carew JS, Nawrocki ST, Giles FJ, Cleveland JL. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics : Targets & Therapy. 2: 201-4. PMID 19707354 DOI: 10.2147/Btt.S1840 |
0.512 |
|
| 2008 |
Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5000-5. PMID 18698017 DOI: 10.1158/1078-0432.Ccr-08-0746 |
0.485 |
|
| 2008 |
Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 112: 2917-26. PMID 18641367 DOI: 10.1182/Blood-2007-12-130823 |
0.635 |
|
| 2008 |
Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA, Marton LJ, Cleveland JL. The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Research. 68: 4783-90. PMID 18559525 DOI: 10.1158/0008-5472.Can-07-6483 |
0.59 |
|
| 2008 |
Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters. 269: 7-17. PMID 18462867 DOI: 10.1016/J.Canlet.2008.03.037 |
0.499 |
|
| 2008 |
Nawrocki ST, Medina E, Smith S, Swords R, Kelly K, Padmanabhan S, Ecsedy J, Giles FJ, Carew J. The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib Blood. 112: 3198-3198. DOI: 10.1182/Blood.V112.11.3198.3198 |
0.523 |
|
| 2008 |
Neuteboom S, Medina E, Palladino M, Spear M, Lloyd G, Nawrocki S. 450 POSTER NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522 European Journal of Cancer Supplements. 6: 141. DOI: 10.1016/S1359-6349(08)72384-X |
0.32 |
|
| 2008 |
Carew J, Medina E, Mita M, Mita A, Giles F, Nawrocki S. 257 POSTER Inhibition of autophagy significantly enhances the anticancer activity of SAHA by promoting ubiquitin-conjugated protein accumulation and oxidative stress in colon cancer cells European Journal of Cancer Supplements. 6: 84. DOI: 10.1016/S1359-6349(08)72191-8 |
0.327 |
|
| 2007 |
Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Research. 67: 6987-94. PMID 17638911 DOI: 10.1158/0008-5472.Can-07-0812 |
0.533 |
|
| 2007 |
Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 3: 464-7. PMID 17495516 DOI: 10.4161/Auto.4311 |
0.528 |
|
| 2007 |
Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 110: 313-22. PMID 17363733 DOI: 10.1182/Blood-2006-10-050260 |
0.53 |
|
| 2006 |
Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Molecular Cancer Therapeutics. 5: 2251-60. PMID 16985059 DOI: 10.1158/1535-7163.Mct-06-0075 |
0.744 |
|
| 2006 |
Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis. 9: 101-10. PMID 16871430 DOI: 10.1007/S10456-006-9038-9 |
0.541 |
|
| 2006 |
Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RHI, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Research. 66: 3773-3781. PMID 16585204 DOI: 10.1158/0008-5472.Can-05-2961 |
0.688 |
|
| 2006 |
Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 107: 222-31. PMID 16144803 DOI: 10.1182/Blood-2005-05-1923 |
0.619 |
|
| 2005 |
Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Research. 65: 11658-66. PMID 16357177 DOI: 10.1158/0008-5472.Can-05-2370 |
0.64 |
|
| 2005 |
Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Research. 65: 11510-9. PMID 16357160 DOI: 10.1158/0008-5472.Can-05-2394 |
0.615 |
|
| 2005 |
Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biology & Therapy. 4: 1263-9. PMID 16319525 DOI: 10.4161/Cbt.4.11.2138 |
0.625 |
|
| 2005 |
McConkey D, Nawrocki ST, Andtbacka R. Velcade displays promising activity in primary effusion lymphoma cells. Cancer Biology & Therapy. 4: 491-2. PMID 15908793 DOI: 10.4161/Cbt.4.4.1645 |
0.608 |
|
| 2004 |
Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia. 18: 1934-40. PMID 15483672 DOI: 10.1038/Sj.Leu.2403545 |
0.509 |
|
| 2004 |
Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biology & Therapy. 3: 1217-24. PMID 15477758 DOI: 10.4161/Cbt.3.12.1221 |
0.696 |
|
| 2004 |
Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemotherapy and Pharmacology. 54: 113-21. PMID 15133625 DOI: 10.1007/S00280-004-0777-2 |
0.342 |
|
| 2004 |
Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Molecular Cancer Therapeutics. 3: 59-70. PMID 14749476 |
0.663 |
|
| 2002 |
Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts Molecular Cancer Therapeutics. 1: 1243-1253. PMID 12516957 |
0.637 |
|
| Show low-probability matches. |